Stoke Therapeutics (STOK) Common Equity (2018 - 2026)

Stoke Therapeutics has reported Common Equity for 9 years, with the latest figure at $394.9 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 12.8% year-over-year to $394.9 million; the trailing twelve-month figure through Mar 2026 stood at $394.9 million (up 12.8% YoY), and the FY2025 full-year result was $352.5 million, up 53.9% from the prior year.
• Common Equity for Q1 2026 stood at $394.9 million, up from $352.5 million in the prior quarter.
• The five-year high for Common Equity was $394.9 million in Q1 2026, with the low at $140.3 million in Q1 2024.
• Average Common Equity over 5 years is $245.6 million, with a median of $229.0 million recorded in 2024.
• Year-over-year, Common Equity slumped 34.37% in 2024 and soared 149.44% in 2025.
• Tracing STOK's Common Equity over 5 years: stood at $184.8 million in 2022, then decreased by 13.68% to $159.6 million in 2023, then soared by 43.53% to $229.0 million in 2024, then soared by 53.9% to $352.5 million in 2025, then climbed by 12.04% to $394.9 million in 2026.
• The last three Common Equity figures came in at $394.9 million (Q1 2026), $352.5 million (Q4 2025), and $308.1 million (Q3 2025), per Business Quant data.

Peer Comparison